Mesoblast gets FDA go ahead for pediatric drug
The US Food and Drug Administration has told biotechnology company Mesoblast that it now has sufficient clinical data to support a submission to approve the company’s remestemcel-L drug for treatment of pediatric patients. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel…